Stay updated on Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page
- CheckyesterdayChange DetectedPage revision updated to v3.4.3; the previous revision v3.4.2 was superseded.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedRevision: v3.4.2 was added and an older funding/operating-status notice was removed; these are minor administrative updates that do not affect the study content or how you interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check37 days agoChange DetectedAdded a government funding lapse notice about data currency and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check44 days agoChange DetectedAdded a 'Show glossary' option and updated the study record to display 'Last Update Submitted that Met QC Criteria' with revision v3.4.0. Removed the older label 'Last Update Submitted that met QC Criteria', adjusted capitalization of 'No FEAR Act Data' to 'No FEAR Act data', and updated the revision from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check58 days agoChange DetectedPage revision history updated: Revision v3.3.4 added and Revision v3.3.3 removed.SummaryDifference0.1%

- Check79 days agoChange DetectedAdded a new Locations section with North Carolina as a study site. Removed the North Carolina Locations entry and the HHS Vulnerability Disclosure link; updated the page revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.